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Why do some patients respond to one type of alco-holism treatment but not to another? Are there pa-
tient characteristics, such as age of onset or a particular 
genotype, that are useful predictors of alcoholism treat-
ment response? These important questions remain to be 
answered. 
To provide a framework for understanding differ-
ential response of early- and late-onset alcoholism sub-
types to treatment with selective serotonin reuptake 
inhibitors (SSRIs) and ondansetron (5-HT3 receptor an-
tagonist), Johnson and colleagues presented a theoretical 
model that incorporated recent empirical findings and 
our current understanding of serotonergic (5-HT) func-
tion (Johnson, 2000; Johnson and Ait-Daoud, 2000). This 
sophisticated descriptive model represents an important 
step in conceptualizing the ways in which genetic varia-
tion for a component in a neurotransmitter system may 
affect alcoholism phenotypes, in this case treatment re-
sponse, taking into account the effects of both acute and 
chronic alcohol exposure and neurotransmitter system 
regulatory mechanisms. 
The model presented by Johnson and colleagues hy-
pothesizes that functional changes in the dopamine 
(DA) system that are an adaptation to genetic or alco-
hol-induced changes in 5-HT function explain why on-
dansetron seems to be an effective alcoholism treatment 
for those with early-onset but not for those with late-
onset alcoholism. This argument assumes that the L/L 
genotype at the 5-HT transporter promoter (5-HTTLPR) 
is more prevalent in those with early-onset alcoholism. 
In the present study, whether the L/L genotype is as-
sociated with early-onset alcoholism is not addressed. 
Because the Johnson model is based on a compari-
son of two functionally different 5-HTTLPR genotypes, 
the genotype is the primary grouping category in this 
study, and issues of alcoholism subtype will be ignored 
for simplicity. 
The main hypothesis generated by the model is that 
alcohol consumption (both chronic and acute) is more 
rewarding (via DA activity) for those with the 5-HT-
TLPR L/L genotype because their dopaminergic neu-
rons possess larger populations of 5-HT3 receptors as a 
result of up-regulation in response to low 5-HT levels. 
Treatment with ondansetron blocks DA activation me-
diated through 5-HT3 receptors, thereby reducing the re-
warding effects of drinking. 
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Serotonergic Agents and Alcoholism Treatment:  
A Simulation
Scott F. Stoltenberg
University of Michigan, Department of Psychiatry, Addiction Research Center, Ann Arbor, Michigan
Abstract
Background: Those with early-onset alcoholism may better respond to ondansetron (a 5-HT3 receptor antagonist) than to selective se-
rotonin reuptake inhibitor (SSRI) treatment, whereas those with late-onset alcoholism may present the reverse response pattern. 
Johnson and colleagues proposed a model that attempts to explain the observed treatment response patterns of those with early 
and late alcoholism onset by focusing on the influence of a common genetic variant in the serotonin transporter regulatory region 
(5-HTTLPR) on serotonin (5-HT) and dopamine (DA) system function.
Methods: The present study formalizes and extends Johnson’s descriptive model into a computer simulation consisting of differential 
equations. For each of 16 conditions defined by genotype, drinking status, diagnostic status, and drug treatment, data were gener-
ated by 100 simulation runs. 
Results: In every condition, the S/_ genotype (S/S and S/L) had higher extracellular 5-HT levels than did the L/L genotype. The S/_ gen-
otype also had higher rates of postsynaptic DA firing than did the L/L genotype with the exception of the SSRI treatment condi-
tion, where the firing rates were similar. Drinking generally increased levels of extracellular 5-HT, reduced rates of presynaptic 5-
HT firing, and increased rates of postsynaptic DA firing. Drinking produced increases in DA activation that were greater for the 
L/L genotype in the SSRI treatment condition and for the S/_ genotype in the ondansetron treatment condition. 
Conclusions: Genotype at 5-HTTLPR may influence relative reward of drinking alcohol while a person is under pharmacological treat-
ment for alcoholism. Alternatively, 5-HTTLPR genotype may influence pathways of alcohol craving. Clinical studies should examine 
these hypotheses. 
Keywords: computational model, serotonin transporter, 5-HT3 receptor, SSRI, ondansetron
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The present study implements Johnson’s model by 
using a system dynamic computer simulation to exam-
ine whether the predictions made by the descriptive 
model are supported by a more rigorous and quanti-
tative model construction. Extensions to the model are 
proposed that will facilitate the exploration of other 
pharmacological treatments for alcoholism and of the 
effects of other genetic variants in the serotonergic neu-
rotransmitter system. 
Methods
Because system dynamic computer simulations are well suited to 
model biological control systems with more precision than a descrip-
tive model (Gallaher, 1996), this report details a system dynamics ver-
sion of the Johnson model. System dynamics is descended from earlier 
work in cybernetics (Wiener, 1961) and general systems theory (von 
Bertalanffy, 1968) regarding feedback and the flow of information in 
systems. Computer simulation can facilitate the generation of testable 
hypotheses when the input is complicated and when feedback loops 
are present and may enable the identification of leverage points by 
which large changes in system behavior can result from small inputs 
(Axelrod, 1997; Gallaher, 1996). 
Software 
This model is an extension of a presynaptic regulatory model of 5-HT 
function (S. F. Stoltenberg, unpublished data, 2003) implemented us-
ing STELLA® Research 6.0 for Windows (Chichalkly et al., 2000), a 
commercially available simulation tool. The simulation runs by iter-
atively solving differential equations. Simulation data were generated 
using Berkeley Madonna 8.0.1 (Zahnley, 2000) for batch runs. 
Equations 
The following calculations were performed 100 times for each of 500 
time steps (i.e., dt = 0.01) for a total of 50,000 calculations per simula-
tion run. 
The change in extracellular 5-HT (dS/dt) was determined by the 
rate of 5-HT flowing out of extracellular space (O) and the rate flow-
ing in (I). 
dS/dt = – O + I                                           (1) 
Input Variables 
We defined inhibitory thresholds (ITs) as the amount of extracellular 
5-HT above which presynaptic 5-HT neural firing is inhibited. That 
is, IT represents the level of somatodendritic autoreceptor sensitivity. 
Initial IT values were set below the level of the average release value 
because it was reasoned that firing should be inhibited if the amount 
of 5-HT remaining in the extracellular space was equal to or greater 
than the average release amount. The assumption is that for proper 
neurotransmission, a substantial amount of neurotransmitter must be 
cleared from the extracellular space before another firing event is per-
mitted to occur. 
When the amount of extracellular 5-HT was below the inhibitory 
threshold, 100 units of 5-HT was released (R), simulating vesicular re-
lease that results from an action potential (i.e., presynaptic neuron fir-
ing event). The release value is rather arbitrary at this level of abstrac-
tion because the important issue here is how these variables relate to 
one another, not whether the parameter values are better suited to 
mice or humans. Direct application of this model to any specific em-
pirical situation runs the risk of drawing attention away from the un-
derlying system dynamics. 
In the present negative feedback model, presynaptic vesicular re-
lease was inhibited when the level of extracellular 5-HT was greater 
than the IT. In the absence of vesicular release, transporter-mediated 
efflux was simulated, referred to here as “leakage” (L). Transporter-
mediated efflux is known to occur through monoamine transporters, 
including serotonin transporter (SERT) (Johnson et al., 1998; Scholze 
et al., 2000), although details of transporter-mediated release in vivo 
are not well understood. To simulate transporter-mediated release in 
the present model, a new value for L was chosen at random from a 
normal distribution with mean R/20 (i.e., 5% of vesicular release) and 
variance of L/10 at each time step. 
if [S]t < IT then It = R,   else It = L                                  (2) 
The amount of 5-HT removed from extracellular space (Ot) was 
modeled as a function of the extracellular clearance rate (CR) rate mul-
tiplied by the amount of extracellular 5-HT. 
Ot = CR * [St]                                                   (3) 
Clearance rate variation mediated by the SERT may be genetic in 
origin (e.g., 5-HTTLPR genotype; Lesch et al., 1996) and altered by 
pharmacological agents (e.g., SSRI). In the present simulation, the 
clearance rate (i.e., SERT function) was modeled as a function of the 
5-HTTLPR genotype (Lesch et al., 1996), chronic alcoholism (Heinz et 
al., 2000), and SSRI treatment condition (Meyer et al., 2001). 
Postsynaptic DA firing was modeled as a binomial variable (i.e., 
0 = no fire, 1 = fire) with probability based on the amount of extracel-
lular 5-HT. Specifically, at each time step, the probability of DA firing 
(DAprob) was binomial with p = [St]/500, which produced DA firing 
probabilities that were proportional to extracellular 5-HT concentra-
tion and provided DA firing rates with adequate range across test con-
ditions. The potentiation of 5-HT3 receptors resulting from low extra-
cellular 5-HT level was modeled by increasing the probability of DA 
firing when extracellular 5-HT levels were below the standard release 
value (i.e., 100). In that case, the probability of DA firing was increased 
in inverse proportion to the level of extracellular 5-HT (i.e., DAprob + 
(1/[St])). 
Random numbers were drawn from normal distributions with 
means and variances specified using a lagged Fibonacci generator 
with a period of approximately 1084 (Zahnley, 2000) for initial sero-
tonin, release, and leakage values. Random number seeds varied for 
each calculation. 
Model Dynamics 
To capture the progressive desensitization that occurs for somato-
dendritic 5-HT autoreceptors, a simple dynamic rule to adjust inhib-
itory threshold was implemented. At each time step, the model eval-
uated whether the system had fired. If the system had not fired (i.e., 
was inhibited by somatodendritic autoreceptors indicating high lev-
els of 5-HT), the IT was increased, which increased the likelihood 
that the system would fire at the next time step. Alternatively, if the 
system had fired, the IT was decreased, which reduced the likeli-
hood that the system would fire at the next time step. The levels of IT 
adjustments were represented by the variables ITUP and ITDOWN. 
Adjustment values were set at 3% of the initial release value (i.e., 3% 
of 100 = 3). 
Another dynamic rule was used to regulate the amount of 5-HT re-
leased, which models the effect of the presynaptic terminal 5-HT au-
toreceptor (5-HT1B). The standard level of release (i.e., 100 units) was 
used when extracellular 5-HT level was between 50 and 150. When the 
level of extracellular 5-HT was low (i.e., below 50), more 5-HT was re-
leased (150 units). Alternatively, when the level of extracellular 5-HT 
was high (i.e., above 150), less 5-HT was released (50 units). 
Outcome Measures 
Level of extracellular 5-HT was one of the main outcome variables of 
interest. For each run of the simulation, the initial starting level of 5-
HT was set at 50. The other main outcome variables were 5-HT and 
DA firing rates defined as the number of times that a system fired (i.e., 
released 5-HT, or activated the postsynaptic DA system) in 500 time 
steps. For each model condition, the mean for 100 simulation runs was 
recorded for extracellular 5-HT level and cumulative 5-HT and DA fir-
ing rates for 500 time steps. 
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Test Conditions 
Serotonin Transporter Genotype. The values for transporter genotype 
were based on the 5-HTTLPR empirical literature, which indicates that 
the L/L genotype has 2- to 3-fold higher activity than either the S/L or 
S/S genotype (Lesch et al., 1996). In the present simulation, the value 
of the L/L genotype was set at 0.90 and the S/_ genotype at 0.30. As a 
result, at any level of extracellular 5-HT, the L/L genotype would re-
move 90%, whereas the S/_ genotype would remove 30%. 
Drinking. Acute alcohol exposure has been shown to increase the 
amount of 5-HT released per action potential by about 200% of base-
line in the nucleus accumbens of rats after ethanol injection (Yan and 
Lewander, 1999). In the drinking conditions tested in the present simu-
lation, we doubled the amount of 5-HT released from the standard level 
of 100 to a random number selected from a normal distribution with 
mean 200 and variance 20. This condition represents acute alcohol expo-
sure. No distinctions were made regarding social drinking history. 
Chronic Alcohol Exposure. Transporter function has been shown 
to be reduced in alcoholic individuals with the L/L but not in those 
with S/_ 5-HTTLPR genotype (Little et al., 1998). In this simulation, 
we examined 5-HT level, 5-HT, and DA firing rates in the L/L geno-
type with chronic alcoholism (i.e., a history of chronic alcohol expo-
sure) by reducing transporter function to 0.495 (i.e., 0.90 × 0.55). We 
did not reduce transporter functioning in the S/_ genotypes in the 
chronic alcoholism condition to be consistent with empirical results 
(Heinz et al., 2000). No distinctions were made regarding family his-
tory of alcoholism. 
SSRI Treatment. SSRIs block reuptake of 5-HT from extracellular 
space via the SERT. At therapeutic SSRI doses for depression, avail-
ability of SERT is reduced relative to baseline by approximately 80% 
(Meyer et al., 2001). In the SSRI condition of the present simulation, we 
reduced transporter function to 20% of the baseline for that genotype. 
Ondansetron Treatment. Ondansetron is a 5-HT3 antagonist (i.e., 
blocker). In the context of this simulation, the presence of ondansetron 
reduced by one half the probability of postsynaptic DA firing. Specif-
ically, in the ondansetron condition, the probability of DA firing was 
based on the binomial with probability p = [St]/1000. 
Data Analysis and Statistics 
The level of extracellular 5-HT reported represents the serotonin value 
at the end of a simulation run (i.e., step 500) averaged over 100 runs. 
The serotonin and dopamine firing rates are the cumulative firing rates 
at step 500 averaged over 100 runs of the simulation. Values are ex-
pressed as percentages of the L/L genotype baseline (i.e., no alcoholism, 
no drinking) levels. Confidence intervals around estimates of means are 
exceedingly small because each value represents a mean of 100 runs. 
For mean extracellular 5-HT level, the largest standard deviation ob-
tained was ± 0.71 in the LASD (L/L genotype, chronic alcoholism, SSRI 
treatment, drinking) condition. For mean presynaptic 5-HT firing rate, 
the largest SD was ± 0.26 in the L (L/L genotype, no drinking, baseline) 
condition. For mean DA firing rate, the largest SD obtained was ± 1.14 in 
the SA (S/_ genotype, chronic alcoholism, no drinking) condition. Data 
are presented in Figs. 1 and 2 as percent change from the L/L genotype 
baseline condition, that is, with no drinking, no chronic alcoholism, and 
no treatment. Differences greater than 5% can be considered statistically 
significant at 2 = 0.01 (Cohen, 1988). 
Results
No Alcoholism 
This is the baseline condition of the model. The mean 
extracellular 5-HT level for the S/_ genotype was 300% 
that of the L/L genotype in the no-drinking condition 
(see Figure 1). Drinking increased 5-HT level for both 
genotypes with a greater relative increase for the S/_ 
genotype (+295% versus +100% for L/L). The mean pre-
synaptic 5-HT firing rate for the S/_ genotype was 92% 
that of the L/L genotype. Drinking decreased the mean 
presynaptic 5-HT firing rate for S/_ (–11%) but not for 
the L/L genotype (–4%). The mean postsynaptic DA fir-
ing rate in the no-drinking condition for the S/_ gen-
otype was 242% that of the L/L genotype. Drinking 
increased the postsynaptic DA firing rate for both gen-
otypes; however, the relative increase was greater for 
the S/_ (+186%) genotype than for the L/L (+69%) gen-
otype. Baseline simulation conditions resulted in differ-
ences among 5-HTTLPR genotypes in extracellular 5-
HT level, presynaptic 5-HT, and postsynaptic DA firing 
rates. As predicted in the Johnson model, the L/L geno-
type was associated with lower extracellular 5-HT lev-
els and lower postsynaptic DA firing rates than the S/_ 
genotype. For both genotypes, drinking increased 5-HT 
Figure 1. Mean extracellular 5-HT level, presynaptic 5-HT firing, and postsynaptic dopaminergic firing for 5-HTTLPR S/_ and L/L genotypes without 
ethanol drinking (i.e., no current acute alcohol exposure) and with ethanol drinking (i.e., acute alcohol exposure) in the normal (no chronic alcohol 
exposure) baseline condition. Data presented are percent change from the baseline L/L genotype. No bars are shown for the L/L genotype because 
values are set at 100%. 
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level and postsynaptic DA firing rate while it decreased 
presynaptic 5-HT firing rates. Contrary to prediction, 
acute ethanol exposure (i.e., drinking) induced increases 
in DA activation that were greater for the S/_ than for 
the L/L genotype. 
Untreated Chronic Alcoholism 
In the no-drinking condition of untreated chronic alco-
holism, mean extracellular 5-HT level for the S/_ geno-
type was higher (300% of L/L baseline) than that of the 
L/L genotype (182% of L/L baseline; see Figure 2A). In 
addition to the effect of untreated chronic alcoholism, 
drinking further raised the mean 5-HT levels for both 
genotypes (S/_ = +295%; L/L = +181%). In the no-drink-
ing condition of untreated chronic alcoholism, presyn-
aptic 5-HT firing rates for the L/L genotype were es-
sentially unchanged (97%) relative to the L/L genotype 
at baseline, whereas those for the S/_ genotype were 
slightly reduced (92%). In addition to the effect of un-
treated chronic alcoholism, drinking further decreased 
mean rates of presynaptic 5-HT firing in the L/L (–7%) 
and the S/_ genotypes (–11%). The mean postsynaptic 
DA firing rate for the S/_ genotype (242% of L/L base-
line) was greater than for the L/L genotype (155% of L/
L baseline) in the no-drinking condition. Drinking fur-
ther raised postsynaptic DA firing rates for both geno-
types with a greater relative increase for the S/_ (+186%) 
than for the L/L genotype (+131%). Genotype differ-
ences in both extracellular 5-HT level and postsynaptic 
DA firing rate were observed in the untreated alcohol-
ism condition, and although the differences were in the 
same direction as observed in the no-alcoholism base-
line condition, they were less pronounced. Drinking in-
creased the level of extracellular 5-HT, increased post-
synaptic DA firing rate, and decreased presynaptic 5-HT 
firing rates. Contrary to prediction, chronic ethanol expo-
sure (i.e., alcoholism) induced increases in DA activation 
that were greater for the S/_ than for the L/L genotype. 
Chronic Alcoholism Treated with SSRI 
Data generated in the SSRI treatment condition were 
compared with those generated in the untreated alco-
holism condition to assess the effect of SSRI alcoholism 
treatment. The increase in mean extracellular 5-HT level 
under SSRI treatment with no drinking relative to the 
untreated alcoholism no-drinking condition was greater 
for the S/_ genotype (+962%) than for the L/L genotype 
(683%; see Figure 2B). Drinking raised the extracellular 
5-HT levels for the two genotypes equally (S/_ = +574%; 
L/L = +572%) relative to the SSRI condition with no 
drinking. In the no-drinking SSRI condition, rates of pre-
synaptic 5-HT firing decreased for both genotypes (L/L 
= –27%, S/_ = –37%) relative to the untreated alcoholism 
no-drinking condition. Drinking in the SSRI treatment 
condition produced a further decrease in the presynap-
tic 5-HT firing rate for both genotypes (L/L = –22%, S/_ 
= –23%) relative to the SSRI condition with no drinking. 
Mean rates of postsynaptic DA firing were elevated for 
both genotypes in the SSRI no-drinking condition rela-
tive to the chronic alcoholism no-drinking condition (L/
L = +408%; S/_ = +378%). Drinking raised the postsyn-
aptic DA firing rates for both genotypes with a larger in-
crease in the L/L group (L/L = +69%; S/_ = +24%) rela-
tive to the SSRI condition with no drinking. During SSRI 
alcoholism treatment, 5-HT level increased for both gen-
otypes relative to the untreated condition. SSRI treatment 
reduced rates of presynaptic 5-HT firing and increased 
rates of postsynaptic DA firing for both genotypes. For 
both genotypes, SSRI treatment condition produced the 
Figure 2. Mean extracellular 5-HT level, presynaptic 5-HT firing, and 
postsynaptic dopaminergic firing for 5-HTTLPR S/_ and L/L genotypes 
with alcoholism (i.e., chronic alcohol exposure), without and with drinking 
(i.e., acute alcohol exposure) for (A) untreated alcoholism, (B) alcoholism 
treated with SSRI, and (C) alcoholism treated with ondansetron. Alcoholism 
is defined as chronic alcohol exposure in this study. Data presented are 
percent change from the L/L genotype no alcoholism baseline condition. 
Note that the y axis for panel B is not the same as the others. 
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highest levels of extracellular 5-HT, the highest postsyn-
aptic DA firing rates, and the lowest presynaptic 5-HT 
firing rates achieved in any test condition.
Chronic Alcoholism Treated With Ondansetron 
For both genotypes, the pattern of results for extracellu-
lar 5-HT level and for presynaptic 5-HT firing rate in the 
ondansetron treatment condition was identical to the pat-
tern observed in the untreated alcoholism condition (Fig-
ure 2C). In this simulation, ondansetron treatment was 
modeled to influence postsynaptic DA firing rate and 
did not affect presynaptic 5-HT function. Postsynaptic 
DA firing rate in the ondansetron no-drinking condition 
was reduced for both genotypes relative to the untreated 
alcoholism condition (S/_ = –121%; L/L = –77%). Drink-
ing increased postsynaptic DA firing rates for both gen-
otypes (S/_ = +94%; L/L = +65%) relative to the ondan-
setron condition with no drinking. For both genotypes, 
ondansetron treatment decreased postsynaptic DA firing 
relative to the untreated alcoholism condition. In fact, 
postsynaptic DA firing rates for the no-drinking ondan-
setron condition were below rates for the no-alcoholism 
L/L genotype baseline. Drinking increased postsynap-
tic DA firing rates for both genotypes, with a greater rate 
of increase observed in the S/_ genotype; however, rates 
remained substantially lower than those observed in the 
untreated alcoholism drinking condition. 
Discussion
The results of this simulation are largely consistent with 
the descriptive model presented by Johnson and col-
leagues (Johnson, 2000; Johnson and Ait-Daoud, 2000). 
The L/L genotype of the 5-HTTLPR variant was associ-
ated with lower extracellular 5-HT level and postsynap-
tic DA firing rates but slightly higher presynaptic 5-HT 
firing rates than the S/_ genotype. Changes in the pat-
tern of simulated presynaptic 5-HT function and post-
synaptic DA activation were in the same direction for 
both genotypes but of different magnitude. 
Both acute (i.e., drinking) and chronic (i.e., alcohol-
ism) alcohol exposure induced increases in DA activa-
tion that were greater in the S/_ than the L/L genotype. 
However, drinking produced increases in postsynaptic 
DA firing that for the L/L genotype were greater in the 
SSRI treatment condition and that for the S/_ genotype 
were greater in the ondansetron treatment condition. If 
DA activation is considered rewarding, drinking is more 
rewarding for those with the L/L genotype under SSRI 
than ondansetron treatment. For those with the S/_ gen-
otype, drinking is more rewarding under ondansetron 
than SSRI treatment. 
Another potential explanation of 5-HTTLPR geno-
type differences in treatment response is to hypothesize 
that the genotypes are associated with different path-
ways of alcohol craving (Verheul et al., 1999). 
The present simulation results suggest that individ-
uals with the L/L genotype may experience “reward 
craving” mediated via dopaminergic activation. On-
dansetron treatment, which reduces DA activation via 
5-HT3 receptor antagonism, has been shown to be effec-
tive in individuals with early-onset alcoholism, which 
often is associated with binge drinking, family history 
of alcoholism, and inability to abstain. These character-
istics define the “dopaminergic/opiodergic dysregula-
tion” pathway in a model of alcohol craving (Verheul et 
al., 1999). Such DA system dysregulation actually may 
be an indirect result of genetic variation that influences 
presynaptic 5-HT function, as demonstrated in the pres-
ent study. 
In the context of the present simulation, reward crav-
ing may be indexed by the postsynaptic DA firing rate 
in the no-drinking condition. The DA-mediated reward 
may be indexed as the difference between the DA firing 
rate in the drinking versus no-drinking conditions. For 
those with the L/L genotype, ondansetron treatment re-
duces both craving and reward (Figure 2C). 
Simulation results suggest that individuals with the 
S/_ genotype may experience “relief craving.” Both al-
cohol drinking and SSRI treatment raise extracellular 5-
HT levels and decrease firing rates of 5-HT neurons, and 
both are used to treat negative affect (i.e., anxiety and 
depression; alcohol via self-medication and SSRI via 
prescription), which is consistent with the relief craving 
pathway model mediated by GABAergic/glutamater-
gic dysregulation (Verheul et al., 1999). Both γ-aminobu-
tyric acid and glutamate are known to influence 5-HT 
neurons in midbrain raphe nuclei (Adell et al., 2002; Tao 
and Auerbach, 2003), and perhaps it is through these in-
teractions that the effect of the 5-HTTLPR genotype is 
manifest. For those with the S/_ genotype, SSRI treat-
ment may raise extracellular 5-HT levels into some tar-
get range and eliminate, or reduce, the urge to raise 5-
HT by drinking. Moreover, it may be that for those with 
the S/_ genotype, drinking while under SSRI treatment 
elevates extracellular 5-HT level excessively. 
Johnson (2000) suggested that for those with the S/_ 
genotype, chronic SSRI treatment would produce a “mod-
est facilitation of 5-HT neurotransmission and long-term 
inhibition of dopaminergic activity, thereby offsetting al-
cohol’s rewarding effects during chronic drinking.” The 
current simulation does not include a mechanism for de-
sensitization of 5-HT3 receptors due to chronic high levels 
of 5-HT. The inclusion of such a mechanism may result in 
a better fit with this particular hypothesis. 
The results of the present simulation suggest that 
those with the S/_ genotype may be sensitive to extra-
cellular 5-HT levels but insensitive to reward via DA ac-
tivation and that those with the L/L genotype may be 
insensitive to extracellular 5-HT levels but sensitive to 
DA-mediated reward, which is consistent with the crav-
ing pathway model (Verheul et al., 1999). 
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Interestingly, the craving pathway model identifies 
an “obsessive craving” pathway that is hypothesized 
to be mediated via “serotonergic dysregulation.” The 
present simulation results suggest that the three craving 
pathways could all be, either indirectly or directly, in-
fluenced by serotonergic regulation. The obsessive crav-
ing pathway could be associated with differences in 5-
HT metabolism or with terminal autoreceptors, each of 
which has been implicated in antisocial alcoholism traits 
in humans (Hill et al., 2002; Lappalainen et al., 1998) and 
in aggression and drinking in mice (Cases et al., 1995; 
Crabbe et al., 1996). We did not test these hypotheses in 
the present study. 
The results of this simple dynamic model should not 
be interpreted to suggest that a common polymorphism 
in the 5-HT transporter causes alcoholism. It is generally 
accepted that alcoholism is a complex disorder that is 
the result of the coaction of multiple genes and multiple 
environmental risk factors. Computer simulations make 
it possible to study multifactorial problems with relative 
ease and facilitate hypothesis generation (Casti, 1997). 
The use of computer simulations to study heredity-be-
havior relations can be referred to as computational be-
havior genetic analysis. 
The results of the present simulation are consistent 
with a craving pathway model (Verheul et al., 1999) and 
a model of alcoholism treatment (Johnson, 2000; John-
son and Ait- Daoud, 2000) and with empirical observa-
tions (Johnson et al., 2002). Simulation results highlight 
opportunities to test hypotheses in humans concerning 
5-HTTLPR genotype and craving and in rodents con-
cerning 5-HT and DA function using microdialysis and 
electrophysiological measures. In addition, by varying 
inhibitory threshold and release parameters, this model 
can be used to explore the potential effects of 5-HT1A 
and 5-HT1B receptor antagonists and agonists alone and 
in combinations with SSRI and ondansetron. 
A limitation to this model is that it does not include 
parameters to account for differences in 5-HT synthe-
sis, metabolism, and other postsynaptic effects that may 
play important roles in 5-HT regulation and function. In 
addition, it is difficult to measure the 5-HT and DA out-
comes in humans, which makes predictions rather dif-
ficult to directly test in humans. And although the 5-
HTTLPR promoter variant is one of the most studied 
candidate genes in psychiatric genetics (Stoltenberg and 
Burmeister, 2000), its effects on synaptic 5-HT levels and 
other aspects of neurotransmission are not well defined. 
On the other hand, interactions among SERT and 5-HT1B 
autoreceptors have been shown, such as 5-HT1B-medi-
ated increases in SERT activity (Daws et al., 2000), but 
have not been accounted for in the present study. In ad-
dition, the effects of chronic ethanol exposure on 5-HT3 
receptors have not been addressed in the simulation, 
which may help to explain why the hypothesized pat-
tern of DA activation (i.e., L/L > S/_) was not observed. 
It remains to be seen whether these limitations affect the 
model’s capacity for improving understanding of the 5-
HT system. 
Conclusion
The results of this simulation suggest that 5-HTTLPR 
genotype may influence relative reward of drinking al-
cohol while a person is under pharmacological treat-
ment for alcoholism. Alternatively, those with the S/_ 
genotype of the serotonin transporter promoter variant 
5-HTTLPR may drink to increase extracellular 5-HT lev-
els, and those with the L/L genotype may drink to in-
crease rates of postsynaptic dopaminergic neural fir-
ing. For the most part, the results of this simulation are 
in line with the predictions of the Johnson model. This 
study demonstrates how a computational behavior ge-
netic analysis approach can be used to rigorously and 
quantitatively examine descriptive theoretical models 
and to generate testable hypotheses. 
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